Baoshan Center for Disease Control and Prevention, Shanghai, People's Republic of China.
Department of Epidemiology, School of Public Health, Nantong University, Nantong, Jiangsu Province, People's Republic of China.
J Orthop Surg Res. 2018 Jul 6;13(1):170. doi: 10.1186/s13018-018-0871-5.
To assess the symptomatic effectiveness and safety of oral symptomatic slow-acting drugs (SYSADOAs) on the treatment of knee and/or hip osteoarthritis, such as chondroitin, glucosamine, and combination treatment with chondroitin plus glucosamine.
We searched electronic database including PubMed, Embase, Cochrane Library, and the reference lists of relevant articles published from inception to May 22, 2018. An updated meta-analysis was performed to assess the effectiveness of these slow-acting drugs for osteoarthritis.
Twenty-six articles describing 30 trials met our inclusion criteria and were included in the meta-analysis. The estimates between chondroitin and placebo showed that chondroitin could alleviate pain symptoms and improve function. Compared with placebo, glucosamine proved significant effect only on stiffness improvement. However, the combination therapy did not have enough evidence to be superior to placebo. Additionally, there was no significant difference in the incidence of AEs and discontinuations of AEs when compared with placebo.
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function. Glucosamine showed effect on stiffness outcome. Regarding on the limited number of combination therapy, further studies need to investigate the accurate effectiveness. This information accompanied with the tolerability and economic costs of included treatments would be conducive to making decisions for clinicians.
评估口服症状缓解慢作用药物（SYSADOAs）治疗膝和/或髋骨关节炎的症状疗效和安全性，如软骨素、氨基葡萄糖，以及软骨素联合氨基葡萄糖的联合治疗。
我们检索了电子数据库，包括 PubMed、Embase、Cochrane 图书馆以及截至 2018 年 5 月 22 日发表的相关文章的参考文献列表。进行了一项更新的荟萃分析，以评估这些用于骨关节炎的慢作用药物的疗效。
有 26 篇描述 30 项试验的文章符合纳入标准，并纳入荟萃分析。软骨素与安慰剂之间的估计值表明，软骨素可以缓解疼痛症状并改善功能。与安慰剂相比，氨基葡萄糖仅在改善僵硬方面具有显著效果。然而，联合治疗没有足够的证据表明优于安慰剂。此外，与安慰剂相比，不良事件的发生率和不良事件的停药率没有差异。
鉴于这些症状缓解慢作用药物的疗效，口服软骨素在缓解疼痛和改善身体功能方面比安慰剂更有效。氨基葡萄糖对僵硬结局有效果。鉴于联合治疗的数量有限，需要进一步研究以确定其确切疗效。这些信息结合了纳入治疗的耐受性和经济成本，将有助于临床医生做出决策。
